BMD4503-2
BMD4503-2 is a quinoxaline derivative with inhibitory activity against LRP5/6-sclerostin interactions. BMD4503-2 restores the activity of the Wnt/β-catenin signaling pathway by competitively binding to the LRP5/6-sclerostin complex. BMD4503-2 can be used in the study of Wnt signaling pathways in bone development, maintenance and osteoporosis[1].
Product Specifications
CAS Number
301357-87-9
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/bmd4503-2.html
Purity
99.21
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC(NC1=CC=C(C=C1)S(=O)(NC2=NC3=CC=CC=C3N=C2NC4=C5C=CC=CC5=CC=C4)=O)=O
Molecular Formula
C26H21N5O3S
Molecular Weight
483.54
References & Citations
[1]Choi J, et al. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors[J]. Bioorganic & Medicinal Chemistry Letters, 2018, 28 (6) : 1116-1121.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
240435-01 250 mg
Na-Boc-Ng-Z-D-2,4-diaminobutyric acid dicyclohexylammonium salt 99+% (HPLC)
Sign In for Pricing
View Details 
240435-02 1 g
Na-Boc-Ng-Z-D-2,4-diaminobutyric acid dicyclohexylammonium salt 99+% (HPLC)
Sign In for Pricing
View Details 240435-03 5 g
Na-Boc-Ng-Z-D-2,4-diaminobutyric acid dicyclohexylammonium salt 99+% (HPLC)
Sign In for Pricing
View Details 
240435-04 25 g
Na-Boc-Ng-Z-D-2,4-diaminobutyric acid dicyclohexylammonium salt 99+% (HPLC)
Sign In for Pricing
View Details